Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

amivantamab

RYBREVANT

amivantamab (RYBREVANT) is a epidermal growth factor receptor inhibitor. Associated with Janssen-Cilag Pty Ltd.

EMA: approved TGA: approved PMDA: approved Antineoplastic and immunomodulating agents (L01) L01FX18
Patents linked 18
Pipeline programs 4
News articles 0
Congress events 3
Drug details — amivantamab
Class
Antineoplastic and immunomodulating agents (L01)
Route
—
Patents
18
Programs
4
Data quality
0.83
← All drugs Manufacturer profile Related patents Pipeline programs Congress events Drug news hub Event calendar

Quick answer

amivantamab (RYBREVANT) is a epidermal growth factor receptor inhibitor. Associated with Janssen-Cilag Pty Ltd.

Key facts

INN amivantamab
Brand RYBREVANT
Mechanism Epidermal growth factor receptor inhibitor
Target Epidermal growth factor receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01FX18
Originator Janssen-Cilag Pty Ltd

Mechanism of action

Epidermal growth factor receptor inhibitor

Primary target: Epidermal growth factor receptor

Approval history

Authority Status Date
EMA approved —
TGA approved —
PMDA approved —

Congress & event coverage

Browse event calendar

Pipeline programs

Search pipeline Sponsor programs
  1. Amivantamab Phase 3 · Janssen Cilag International · Colorectal Neoplasms
  2. M25-713 Phase 3 · AbbVie Deutschland GmbH · Non-Small Cell Lung Cancer
  3. A Phase 1 for Advanced Non-Small Cell Lung Cancer Phase 1 · Janssen-Cilag International N.V · Advanced Non-Small Cell Lung Cancer
  4. ORIC-114 Dose 1 + amivantamab Phase 1 · Topiloric/Uriadec · Solid Tumors

Related & competitor drugs

Browse all drugs
  1. abiraterone acetate Antineoplastic and immunomodulating agents (L02)
  2. anagrelide Antineoplastic and immunomodulating agents (L01)
  3. apremilast Antineoplastic and immunomodulating agents (L04)
  4. arsenic trioxide Antineoplastic and immunomodulating agents (L01)
  5. axitinib Antineoplastic and immunomodulating agents (L01)
  6. azacitidine Antineoplastic and immunomodulating agents (L01)

Related patents

Browse patents Janssen-Cilag Pty Ltd patent hub

  1. US 11565096

    Delivery system for a pharmaceutical, holistic or medicinal component

    Expires Mon Jan 26 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11090396

    Compounds and methods for the detection of TRPV-6 cancers and drug delivery

    Expires Mon Aug 12 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11083635

    Tampon delivery system for a pharmaceutical, holistic or medicinal component

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10568863

    CPC distribution chromatography of cannabinoids

    Expires Mon Feb 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10485841

    Method for producing dry extracts

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10399994

    Compounds and methods for preventing or treating sensory hair cell death

    Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10064964

    Compounds and methods for the detection of TRPV-6 cancers and drug delivery

    Expires Mon Aug 30 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9980999

    Method for producing dry extracts

    Expires Mon May 24 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9493482

    Compounds and methods for preventing or treating sensory hair cell death

    Expires Mon Nov 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9486489

    Method for producing dry extracts

    Expires Mon Nov 03 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 8962817

    Vectors encoding a paralytic peptide

    Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 8673858

    Method for treating wrinkles using a paralytic peptide from the shrew Blarina brevicauda

    Expires Mon Mar 13 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 8338136

    Method of producing a paralytic peptide

    Expires Mon Dec 20 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 8003754

    Paralytic peptide for use as a insecticide

    Expires Mon Aug 18 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7413754

    Use of extracts of the genus Cimicifugaas organoselective medicines for treating diseases of the genitourinary system caused by sex hormones

    Expires Mon Aug 14 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 6635672

    Agent for lowering prolactin

    Expires Mon Oct 16 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  17. US 6238671

    Process for the gentle recovery of extract fractions from hypericum, pharmaceutical preparations containing the same and their use

    Expires Mon May 24 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

  18. US 6068816

    Process for the mild reduction of germs in pharmaceutical preparations

    Expires Mon May 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

    expired

Frequently asked questions

What is amivantamab?

amivantamab (RYBREVANT) is a epidermal growth factor receptor inhibitor. Associated with Janssen-Cilag Pty Ltd.

What is the brand name for amivantamab?

RYBREVANT is a marketed brand name for amivantamab. Check FDA Drugs@FDA for the current US label holder and prescribing information.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.